This week, I’m rerunning some popular posts while I prepare for this Friday’s video webinar: Drug Channels Outlook 2021.
Drug pricing perceptions always seem to lag reality. Consider HHS's “Most Favored Nation” model for Medicare Part B. HHS relied in part on a highly misleading ASPE study of 2018 data. Conveniently for HHS, ASPE's analysis stopped before the biosimilar boom began.
Click here to see the original post and comments from October 2020.
The biosimilar market is finally beginning to fulfill its promise.
The latest data show that provider-administered biosimilar drugs are successfully displacing their reference biological products. As I predicted last year, newer biosimilars are being adopted quickly, and their prices are declining rapidly. What’s more, manufacturers of reference products are cutting drug prices to defend their market shares.
Last year, Dr. Scott Gottlieb, a former FDA commissioner, argued that we shouldn’t give up on biosimilars and prematurely regulate prices. As you will see below, Dr. Gottlieb was right.
Read more »
Source: Post feed
